Toggle navigation
Home
Medical
FDA Approves Adalimumab Biosimilar in High-Concentration Form
17-8-2022
Medical
https://www.medscape.com/cx/rssfeeds/2700.xml
84
The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart. FDA Approvals
Share
Tweet
+1
Read The Rest
at : https://www.medscape.com/cx/rssfeeds/2700.xml
Related News
FDA Approves Botox Competitor That Lasts Longer
Excess weight, not high blood sugar, associated with...
High fluoride toothpaste
High-tech Advancements in Cosmetic Dentistry
A Sixth Form Science Student's Reading List 2021
Why Dental Assistants Are in High Demand
STAT+: Pharmalittle: FDA approves a gene therapy for a...
Dentists should give antibiotics to high-risk patients to...
FDA Approves First Gene Therapy for Beta-Thalassemia
How Georgia reduced heat-related high school football deaths